Suppr超能文献

老年人慢性便秘的治疗:最新进展

The treatment of chronic constipation in elderly people: an update.

作者信息

Bosshard Wanda, Dreher Rebecca, Schnegg Jean-François, Büla Christophe J

机构信息

Division of Geriatric Medicine and Geriatric Rehabilitation, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

出版信息

Drugs Aging. 2004;21(14):911-30. doi: 10.2165/00002512-200421140-00002.

Abstract

Constipation is a common problem in elderly persons, with prevalence ranging from 15% to 20% in the community-dwelling elderly population and up to 50% in some studies of nursing home residents. In these patients, constipation results from a combination of risk factors, such as reduced fibre and fluid intake, decreased physical activity resulting from chronic diseases and multiple medications. Despite the high prevalence of constipation, there is surprisingly little evidence available on which to base management decisions of this common condition. Increased fluid intake, regular physical activity and high fibre intake are usually proposed as first step nonpharmacological measures. However, adherence to these measures is limited and pharmacological treatment is frequently required. Data are too limited, especially in elderly persons, to formally recommend one class of laxatives over another or one agent over another within each class. However, bulk-forming and osmotic laxatives are usually recommended as first-line agents, even though data on their effectiveness are limited. The need to maintain good hydration is a limitation in the use of bulk-forming laxatives, in particular, in frail elderly patients. In these patients, polyethylene glycol, an osmotic agent, is an attractive alternative. In addition, it has been shown to relieve faecal impaction in frail patients with neurological disease. Its cost and potential danger in patients at high risk for aspiration is, however, a limitation. Stimulant laxatives are considered mainly as an intermittent treatment in patients who do not respond to bulk-forming or osmotic laxatives. Several promising compounds such as the new serotonin 5-HT4 receptor agonists (tegaserod, prucalopride) and neurotrophin-3 (NT3) have not been adequately tested in older individuals. They are not routinely used and their role in the management of constipation in these patients will be more precisely defined in the future. Other treatment options are available (acupuncture, biofeedback, botulinum toxin and surgery), but experience with these interventions in elderly patients is limited and their indications in this population remain to be clarified. Management of constipation in elderly persons depends largely on experience and beliefs. Several new compounds seem promising but will need to be specifically tested in this population before being recommended.

摘要

便秘是老年人常见的问题,在社区居住的老年人群中患病率为15%至20%,在一些针对养老院居民的研究中高达50%。在这些患者中,便秘是由多种风险因素共同作用导致的,如膳食纤维和液体摄入减少、慢性病导致的身体活动减少以及多种药物的使用。尽管便秘的患病率很高,但令人惊讶的是,关于这种常见病症管理决策的依据却很少。增加液体摄入、定期进行体育活动和高纤维饮食通常被提议作为第一步非药物治疗措施。然而,对这些措施的依从性有限,常常需要进行药物治疗。数据非常有限,尤其是在老年人中,以至于无法正式推荐某一类泻药优于另一类,或在每一类中推荐某一种药物优于另一种。然而,容积性泻药和渗透性泻药通常被推荐作为一线药物,尽管关于它们有效性的数据有限。保持良好的水合状态的需求限制了容积性泻药的使用,特别是在体弱的老年患者中。在这些患者中,渗透性药物聚乙二醇是一种有吸引力的替代药物。此外,它已被证明可缓解患有神经疾病的体弱患者的粪便嵌塞。然而,其成本以及对有吸入高风险患者的潜在危险是一个限制因素。刺激性泻药主要被视为对容积性或渗透性泻药无反应患者的间歇性治疗药物。几种有前景的化合物,如新的5-羟色胺5-HT4受体激动剂(替加色罗、普芦卡必利)和神经营养因子-3(NT3),尚未在老年人中进行充分测试。它们未被常规使用,但它们在这些患者便秘管理中的作用将在未来得到更精确的界定。还有其他治疗选择(针灸、生物反馈、肉毒杆菌毒素和手术),但在老年患者中使用这些干预措施的经验有限,它们在这一人群中的适应证仍有待明确。老年人便秘的管理很大程度上取决于经验和观念。几种新化合物似乎有前景,但在被推荐之前需要在这一人群中进行专门测试。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验